Why the study?
Evidence from studies of vasoactive agents in CS carries uncertainties and variable methodological quality due to inherent study conduct difficulties, while vasopressors and inotropes maintain a fundamental role.
Vasopressors and inotropes remain the cornerstone of pharmacological therapy for cardiogenic shock despite limited high-quality evidence.
Continue mainstay use in cardiogenic shock absent alternatives; leaves open need for rigorous trials on optimal agents.
The evidence from the studies of vasoactive agents in CS carries uncertainties. The methodological quality between the studies is variable due to the inherent difficulties to conduct a study in CS. Vasopressors and inotropes continue to have a fundamental role given the lack of pharmacological alternatives.
No takes yet. Share an insight, caveat, or question.
Kaddoura et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: